{"id":"NCT00680953","sponsor":"Daiichi Sankyo Co., Ltd.","briefTitle":"Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis","officialTitle":"A Randomized, Double-Blind, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of Denosumab in Japanese Osteoporotic Subjects With Prevalent Fragility Vertebral Fracture(s)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2012-06","completion":"2012-07","firstPosted":"2008-05-20","resultsPosted":"2014-02-26","lastUpdate":"2015-03-12"},"enrollment":1262,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoporosis"],"interventions":[{"type":"DRUG","name":"Denosumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Alendronate sodium hydrate","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"},{"label":"3","type":"ACTIVE_COMPARATOR"}],"summary":"Evaluate the efficacy and safety of denosumab in the treatment of involutional (postmenopausal and senile) osteoporotic subjects with prevalent fragility vertebral fracture(s)","primaryOutcome":{"measure":"Incidence of New or Worsening Vertebral Fractures in Osteoporotic Subjects Treated With Denosumab Compared to Placebo","timeFrame":"Baseline to 24 months","effectByArm":[{"arm":"Denosumab","deltaMin":3.6,"sd":null},{"arm":"Placebo","deltaMin":10.3,"sd":null},{"arm":"Alendronate","deltaMin":7.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0001"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":4,"countries":["Japan"]},"refs":{"pmids":["24646104","25403903","32839843"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":65,"n":475},"commonTop":["Nasopharyngitis","Contusion","Dental caries","Osteoarthritis","Back pain"]}}